Item 8.01 Other Events

On May 2, 2022, Alaunos Therapeutics, Inc. (the "Company") issued a press release announcing the dosing of the first patient in its TCR-T Library Phase 1/2 Trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications using the Company's non-viral Sleeping Beauty transposon/transposase technology. The Company continues to expect to announce interim data from the TCR-T Library Phase 1/2 Trial in the second half of 2022. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits.

Exhibit
  No.       Description

99.1          Press Release, dated May 2, 2022.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses